Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00099
|
|||||
| Drug Name |
Iloprost
|
|||||
| Synonyms |
ILOPROST; Ciloprost; Ventavis; Iloprostum; Endoprost; Ilomedin; ZK 36374; 78919-13-8; CHEMBL494; Iloprostum [Latin]; [3H]-Iloprost; Ventavis (TN); ZK-36374; (16R,S)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2; (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; SR-05000001498; Iloprost [USAN:INN:BAN]; Ilomedine; BAY Q6256; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Pulmonary arterial hypertension [ICD11: BB01.0] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H32O4
|
|||||
| Canonical SMILES |
CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O
|
|||||
| InChI |
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
|
|||||
| InChIKey |
HIFJCPQKFCZDDL-ACWOEMLNSA-N
|
|||||
| CAS Number |
CAS 78919-13-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 360.5 | Topological Polar Surface Area | 77.8 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.8
|
|||||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
CHEBI:63916
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP2A1 | Transporter Info | Organic anion transporting polypeptide 2A1 | Substrate | [2] | |
| OATP3A1 | Transporter Info | Organic anion transporting polypeptide 3A1 | Substrate | [3] | ||
| References | ||||||
| 1 | Iloprost was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. | |||||
| 3 | Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.